Holen Sie sich die Stockscreener-App
40.85
35.67%
10.74
Handel nachbörslich:
41.68
0.83
+2.03%
Schlusskurs vom Vortag:
$30.11
Offen:
$37
24-Stunden-Volumen:
40.96M
Relative Volume:
18.51
Marktkapitalisierung:
$4.77B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-472.34M
KGV:
-9.8531
EPS:
-4.1459
Netto-Cashflow:
$-340.33M
1W Leistung:
+36.39%
1M Leistung:
+20.54%
6M Leistung:
+26.35%
1J Leistung:
+55.62%
1-Tages-Spanne:
$36.34
$41.73
1-Wochen-Bereich:
$28.40
$41.73
52-Wochen-Spanne:
$24.78
$43.15
Viking Therapeutics Inc Stock (VKTX) Company Profile
Firmenname
Viking Therapeutics Inc
Sektor
Branche
Telefon
858-704-4660
Adresse
9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA
Compare VKTX vs VRTX, REGN, MRNA, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VKTX
Viking Therapeutics Inc
|
40.85 | 3.73B | 0 | -472.34M | -340.33M | -4.1459 |
VRTX
Vertex Pharmaceuticals Inc
|
514.99 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.90 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
182.56 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
963.79 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
368.08 | 39.20B | 5.76B | 514.49M | 1.10B | 4.4813 |
Viking Therapeutics Inc Stock (VKTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-26 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-10-29 | Eingeleitet | Canaccord Genuity | Buy |
| 2025-04-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-04-08 | Eingeleitet | Goldman | Neutral |
| 2025-02-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-02-07 | Eingeleitet | Citigroup | Neutral |
| 2024-12-02 | Eingeleitet | Piper Sandler | Overweight |
| 2024-11-22 | Eingeleitet | B. Riley Securities | Buy |
| 2024-11-04 | Bestätigt | H.C. Wainwright | Buy |
| 2024-09-11 | Eingeleitet | JP Morgan | Overweight |
| 2024-06-27 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-05-16 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-03-26 | Bestätigt | Oppenheimer | Outperform |
| 2024-03-07 | Eingeleitet | Jefferies | Buy |
| 2024-02-28 | Bestätigt | Oppenheimer | Outperform |
| 2023-05-31 | Fortgesetzt | ROTH MKM | Buy |
| 2023-03-28 | Bestätigt | Maxim Group | Buy |
| 2023-03-17 | Eingeleitet | Stifel | Buy |
| 2021-07-29 | Fortgesetzt | BTIG Research | Buy |
| 2021-05-25 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2020-06-05 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-05-05 | Eingeleitet | Chardan Capital Markets | Buy |
| 2020-05-01 | Eingeleitet | BTIG Research | Buy |
| 2019-07-16 | Eingeleitet | Oppenheimer | Outperform |
| 2019-06-25 | Eingeleitet | Stifel | Buy |
| 2019-03-29 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-03-14 | Bestätigt | Maxim Group | Buy |
| 2019-02-22 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2018-12-12 | Eingeleitet | B. Riley FBR | Buy |
| 2018-11-19 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2018-09-18 | Bestätigt | H.C. Wainwright | Buy |
| 2018-09-18 | Bestätigt | Maxim Group | Buy |
| 2018-09-18 | Bestätigt | Raymond James | Outperform |
| 2018-07-20 | Eingeleitet | SunTrust | Buy |
| 2018-06-28 | Eingeleitet | Raymond James | Outperform |
| 2018-06-01 | Bestätigt | Laidlaw | Buy |
| 2018-05-31 | Bestätigt | Maxim Group | Buy |
| 2018-03-26 | Fortgesetzt | H.C. Wainwright | Buy |
| 2017-11-28 | Bestätigt | Maxim Group | Buy |
| 2017-11-21 | Eingeleitet | ROTH Capital | Buy |
Alle ansehen
Viking Therapeutics Inc Aktie (VKTX) Neueste Nachrichten
VKTX Stock Edges Higher In August Ahead Of Early-Stage Obesity-Drug Data Release In Q3 - Stocktwits
VKTX Stock Clocks Best Day In Nearly 3 Months On Obesity Pipeline Optimism, Buyout Speculation - Stocktwits
VKTX Stock Steady After-Hours On Positive Obesity Drug Pipeline Progress - Stocktwits
Viking Therapeutics Moves Closer To Challenging Ozempic With Phase 3 Trial Progress - Stocktwits
VKTX Stock Has Nearly 300% Wall Street Upside — Is Viking’s Oral Obesity Pill The Next Novo Nordisk-Style Breakout? - Stocktwits
LLY, NVO Stocks Led May’s GLP-1 Rally — But This Smaller ‘Differentiated Player’ Got A Bold 160% Upside Call - Stocktwits
Is It Worth Investing in Viking Therapeutics (VKTX) Based on Wall Street's Bullish Views? - Yahoo Finance
Viking Therapeutics Aims High at $92 Target, But Clinical Risks Remain - NAI500
Viking Therapeutics, Inc. (VKTX) Declines More Than Market: Some Information for Investors - Yahoo Finance
Axsome Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? - fool.com
Viking Therapeutics, Inc. (VKTX) Stock Price, News, Quote & History - Yahoo Finance
Analysts Have a $92 Target on Viking Therapeutics. Here's What Has to Go Right to Get There. - The Motley Fool
NFLX: Netflix Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Viking Therapeutics, Inc. (VKTX) Sees a More Significant Dip Than Broader Market: Some Facts to Know - Yahoo Finance
Viking Therapeutics options flow signals binary event bet ahead of VK2735 readout - investing.com
Novo Nordisk's Semaglutide Meets Goal in Pediatric Obesity Study - Zacks Investment Research
Kuehn Law Encourages Investors of Viking Therapeutics, Inc. to Contact Law Firm - Eastern Progress
VKTX Stock Rallies After Hours On Optimism Around Company’s Obesity Pipeline - Stocktwits
VKTX Stock On Track For Five Consecutive Days Of Gains — Viking Launches Human Trial For Novel Obesity Drug VK3019 - Stocktwits
Viking Therapeutics Trades Well Below Its Wall Street Targets. Here's the Skeptics' Case. - The Motley Fool
Viking Therapeutics (VKTX) Gains Ahead Of Earnings As Its Obesity Narrative Keeps Fair Value In Focus - simplywall.st
Is Viking Therapeutics (VKTX) Stock Fully Priced After A 411% Run? - Yahoo! Finance Canada
Viking Therapeutics Inc. (VKTX) Peer Comparison – Compare with Others - Value Research
VKTX Stock Price, Quote & Chart - ChartMill
Viking Therapeutics, Inc. (VKTX) Outperforms Broader Market: What You Need to Know - finance.yahoo.com
3 Wall Street Analysts Think Viking Therapeutics Stock Will Roughly Triple Over the Next 12 Months. Here's Why I Think They're Wrong - The Motley Fool
Viking Therapeutics to present at three major h... - Pluang
Viking Therapeutics to Participate at Upcoming Investor Conferences - PR Newswire
Will Upcoming Oral VK2735 Late-Stage Trials Change Viking Therapeutics' (VKTX) Obesity Drug Narrative? - simplywall.st
Viking Therapeutics (VKTX) Stock Still Looks Stretched After A 382% Run - simplywall.st
Viking Therapeutics Stock Is Down 66% From Its Peak. Here's What Comes Next. - The Motley Fool
Viking Therapeutics (VKTX) On VK2735 Progress Is Valuation Running Ahead Of The Story - simplywall.st
Viking Therapeutics Stock (VKTX) Opinions on Phase 3 Obesity Drug Data Timing - Quiver Quantitative
6,189,649 Shares in Viking Therapeutics, Inc. $VKTX Purchased by BlackRock Inc. - InsuranceNewsNet
Viking Therapeutics Has $502 Million in Cash and 1 Big Catalyst Left in 2026 -- Is That Enough? - The Motley Fool
VKTX Stock Draws Fresh Attention Ahead Of Earnings: Wall Street Sees Over 170% Upside As GLP-1 Race Burns Hot - Stocktwits
VKTX Eyes Worst Week Since November As Trial Data Looms — Wall Street Still Sees 200% Upside - Stocktwits
A New GLP-1 Challenger? Early Data Shows Viking's New Obesity Drug Tops Novo Rival - Stocktwits
Finanzdaten der Viking Therapeutics Inc-Aktie (VKTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Viking Therapeutics Inc-Aktie (VKTX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| ZANTE GREG | Chief Financial Officer |
Jul 29 '26 |
Sale |
33.47 |
21,217 |
710,141 |
212,204 |
| Mancini Marianna | Chief Operating Officer |
Jul 29 '26 |
Sale |
33.47 |
18,217 |
609,636 |
422,760 |
0.14%
0.15%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):